Glaxosmithkline Share News (GSK)
GSK Share
GSK Share
GSK Share
GSK Share
GSK
GSK Share
GSK Level 2
GSK Live
GSK Broker
GSK Directors
GSK Financial
GSK
GSK Short
GSK
Last checked at -
March 26 (Reuters) - Merck and Co Inc and GlaxoSmithKline Plc are not reimbursing drug co-payments for patients who purchase their health insurance through state and federal exchanges set up under the Obamacare program. The two drugmakers said their decision, first reported by Bloomberg New
Read more(Updates with company statement, paragraphs 4-7) March 26 (Reuters) - Some bottles of Alli, GlaxoSmithKline Plc's weight-loss drug sold over the counter in the United States, have been tampered with, and the Food and Drug Administration was investigating, the company said on Wednesday. <
Read more* Sunstone Capital considers listing Santaris Pharma * Decision on IPO will probably be made this year * Sunstone says prefers U.S. listing due to better analyst coverage (Adds financial details) By Teis Jensen and Ole Mikkelsen COPENHAGEN, March 26 (Reuters) - Danish ve
Read more
European regulatory approval has been granted to GlaxoSmithKline's albiglutide treatment for type two diabetes. GSK expects to launch albiglutide, which is branded Eperzan and is still underdoing its US approval process, in several countries in Europe in the second half of the year, with additiona
Read more* Women now hold fifth of FTSE 100 board positions * Few women on executive committees with only 4 CEOs * Campaigners push for voluntary change, not quotas (Adds new quotes, numbers, after report launch) By Belinda Goldsmith LONDON, March 26 (Reuters) - More women are si
Read moreMarch 26 (Reuters) - GlaxoSmithKline Plc said some bottles of its weight-loss drug Alli bought in the United States had been tampered with and that the U.S. Food and Drug Administration was investigating. Consumers reported that some bottles bought in stores in seven states contained produc
Read moreMarch 26 (Reuters) - GlaxoSmithKline Plc said on
Wednesday that it had received European marketing approval for
its once-weekly diabetes drug albiglutide, which it is marketing
as Eperzan. The drug received a positive recommendation from the
European Medicines Agency (EMA) in January.
LONDON (Alliance News) - The UK government has raised a further GBP4.20 billion from its second sale of Lloyds Banking Group PLC shares, meaning it has now recouped GBP7.41 billion of the roughly GBP21 million that taxpayers injected into the bank during the financial crisis.<
Read moreLONDON (Alliance News) - GlaxoSmithKline PLC Wednesday said it had withdrawn its European marketing authorisation application for the combined use of Meikinist and Tafinlar for the treatment of unresectable or metastatic melanoma with a BRAF V600 mutation. This was as a result of the Commit
Read moreLONDON (Alliance News) - The following is a summary of top news stories Wednesday.
----------
COMPANIES
----------
The UK government said it has raised GBP4.2 billion in its sale of a second tranche of Lloyds Banking Group
LONDON, March 26 (Reuters) - A combination treatment from GlaxoSmithKline for melanoma, the deadliest form of skin cancer, has been delayed in Europe after regulators said they needed more information. Britain's biggest drugmaker said on Wednesday it had withdrawn its application and would
Read moreLONDON (Alliance News) - GlaxoSmithKline PLC Wednesday said it had withdrawn its marketing authorisation application for the combined use of Meikinist and Tafinlar for the treatment of unresectable or metastatic melanoma with a BRAF V600 mutation in Europe. This was as a result of the Commi
Read moreComplaints about insufficient information has led GlaxoSmithKline to temporarily withdraw a European regulatory application for the combined use of two drugs to treat certain cancers. The FTSE 100 company had applied to the European Medicines Agency (EMA) to gain approval to market its trametinib/
Read more* Final Phase III results due by late September * Sanofi hopes to deliver first doses in late 2015 * Sanofi has spent over 1.3 bln euros on project * Sales could top 1 bln euros but project is risky -analysts By Natalie Huet and Noëlle Mennella NEUVILLE-SUR-SAONE, F
Read moreLAGOS, March 25 (Reuters) - The Nigerian unit of British drugmaker GlaxoSmithKline on Tuesday reported 2013 pretax profit up 3.4 percent to 4.31 billion naira ($26 million), from 4.17 billion naira the previous year. Turnover grew 15.3 percent to 29.18 billion naira during the period, comp
Read more
Last checked at